(REDWOOD CITY, CA, January 13, 2019) –Having recently secured $35M in Series B funding, Exo (pronounced “Echo”) Imaging is now accelerating its efforts to develop innovative technologies that will simplify, streamline and increase accessibility to medical imaging through the power of artificial intelligence (AI).
AI TECHNOLOGY AT CORE OF NEW IMAGING PLATFORM FROM EXO
EXO TECHNOLOGY TO HELP HEALTHCARE PROVIDERS DELIVER BETTER, FASTER AND MORE ACCURATE CARE
(REDWOOD CITY, CA, November 5, 2019) - After securing $35 million in Series B capital funding this summer, Exo (pronounced “Echo”) Imaging continues to expand its team with proven leaders that have extensive ultrasound experience to lead the business from ideation to commercialization.
TOP ULTRASOUND INDUSTRY TALENT JOINING EXO IMAGING
MEDICAL IMAGING STARTUP MAKES KEY ADDITIONS TO COMMERCIALIZATION AND PRODUCT TEAMS
Exo Imaging, Inc., a company pioneering a high-performance ultrasound platform based on patented Piezoelectric Micromachined Ultrasonic Transducers (pMUT) technology and artificial intelligence (AI) for imaging and therapeutic applications, announced a $35M Series B financing round. The company was founded in 2015 and has raised nearly $50M to date. Intel Capital led the Series B. Other investors in Exo include: Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund, and Wanxiang Healthcare Investments.
Exo Imaging Emerges from Stealth Mode with $35M Series B Financing Round to Advance Development of the Exo Ultrasound Platform